NIH Runs a Different Subaward Rule Than Every Other Agency, and the CR Just Locked It In

There is a category of grants compliance problem that costs institutions real money without ever producing a headline. It happens when two sets of rules that are supposed to be identical quietly stop being identical, and nobody rewires the accounting system to notice.

NIH created exactly that situation on April 20, 2026, with NOT-OD-26-072, "Update – NIH Implementation of Uniform Administrative Requirements for Federal Financial Assistance." The notice rescinded two flexibilities NIH had adopted a year earlier under NOT-OD-25-059, both drawn from the 2024 revisions to the Uniform Guidance:

• The modified total direct cost definition at 2 CFR 200.1, which had raised the per-subaward base for facilities and administrative cost recovery from $25,000 to $50,000.
• The de minimis indirect cost rate at 2 CFR 200.414(f), which had risen from 10 percent to 15 percent for recipients without a current negotiated rate.

Both reverted. NIH F&A can once again be charged only on the first $25,000 of each subaward, and organizations without a negotiated rate are back to 10 percent.

Five months later, that reversion stopped being a transitional annoyance and became the settled planning baseline. NOT-OD-26-131, released September 28, 2026, confirmed that all FY 2026 fiscal policies remain in effect under the continuing resolution through December 11, 2026 — and the same statute, through its Section 157, bars implementation of the Uniform Guidance revisions that would have resolved the split. Every NIH budget drafted this autumn is being built in a two-threshold world with no regulatory exit before mid-December.

Why NIH Had to Do It

The reversion was not a policy preference. NIH said plainly that although it had incorporated the 2024 Uniform Guidance updates, the FY 2026 appropriations law requires that the indirect cost provisions in 45 CFR Part 75 continue to apply to NIH awards.

The operative rider, catalogued among the FY 2026 legislative mandates in NOT-OD-26-060 as Section 224, directs that the 45 CFR Part 75 indirect cost provisions "shall continue to apply… to the same extent and in the same manner as such provisions were applied in the third quarter of fiscal year 2017."

That sentence is the whole story, and it is worth sitting with. Congress did not legislate a threshold. It legislated a date — and froze NIH's indirect cost practice at a specific quarter nearly a decade in the past. 45 CFR 75 is HHS's own codification of the Uniform Guidance, and as it stood in Q3 FY 2017 it carried the original $25,000 subaward figure and the original 10 percent de minimis rate. When OMB modernized 2 CFR 200 in 2024, HHS's frozen snapshot did not follow.

The rider was written to stop NIH from cutting indirect cost rates. It was the statutory backstop that blocked the proposed 15 percent cap on negotiated F&A rates, and it has been invoked repeatedly in the litigation and appropriations fights that followed, including the restoration of negotiated rates at other agencies through HR 6938. A provision designed as protection turned out to be symmetric: it prevents NIH from lowering indirect cost recovery, and it equally prevents NIH from raising it. The 2024 flexibilities were increases, so they had to go.

This is an underappreciated lesson about how research-funding protections get drafted. Pinning an agency to a historical baseline freezes the whole framework, not just the parts you were worried about.

The Two-Threshold Problem Is an Accounting Problem, Not a Policy One

Here is where institutions actually lose money and invite audit findings.

For an NSF, DOE, USDA, or NASA subaward, F&A applies to the first $50,000 and a recipient without a negotiated rate may use 15 percent. For an NIH subaward on the same campus, in the same month, administered by the same office, it is $25,000 and 10 percent.

Most institutional accounting systems were configured once, in 2024 or 2025, to implement the Uniform Guidance update. They encode a single threshold. They do not branch on funding agency. Which means that unless someone has gone in and built the exception, the system is currently calculating NIH subaward F&A on a $50,000 base and will keep doing so until an auditor finds it.

The exposure compounds in three directions:

Proposal budgets already submitted. Any NIH application built between the 2025 flexibility notice and the April 2026 rescission used the higher base. Those budgets are now wrong, and the error surfaces at just-in-time or at award negotiation — the worst possible moment, because the fix reduces recoverable indirect costs and the direct-cost science has already been scoped.

Subawards already executed. A subaward issued at a 15 percent de minimis rate to a community partner, a small nonprofit, or a clinical site without a NICRA now carries a rate NIH will not reimburse. Someone absorbs the five-point difference, and it will not be NIH.

Subrecipient cost reports in flight. Invoices already submitted and paid at the higher figures may require adjustment and, in some cases, refund.

COGR's Points to Consider in Application of NIH's Grants Policy Notice NOT-OD-26-072, published in May 2026, named the central ambiguity directly: it is not clear how prospectively versus retrospectively the rescission is meant to apply. COGR flagged the resulting compliance complexity, warned that the administrative and financial burden falls hardest on institutions with limited resources, and took the unusual step of recommending that institutions consult legal counsel on implementation. That recommendation tells you how unsettled the retroactivity question was.

NIH released FAQs in August 2026 addressing the $25,000 threshold and indirect cost support for recipients without established rates — four months after the notice, which is itself a measure of how much confusion the reversion generated.

Who Actually Pays

The arithmetic falls unevenly, and the pattern is not flattering.

Consortium-heavy and multi-site projects take the largest absolute hit. On a project with eight subawards, the threshold change removes F&A recovery on $25,000 of base per subaward — $200,000 of base. At a typical negotiated on-campus rate, that is a five-figure annual reduction in recovered indirect costs, repeated every year of the project. Nothing about the administrative work of managing eight subrecipients got cheaper; only the reimbursement did.

Organizations without a negotiated rate lose a third of their indirect recovery. Going from 15 percent back to 10 percent is a one-third cut in the only overhead mechanism available to entities that have never had a NICRA — which describes most community-based organizations, small clinical practices, patient advocacy groups, tribal organizations, and the community partners that NIH's own community-engaged research priorities depend on. These are precisely the organizations with no reserves to absorb it and no staff to notice the change happened.

Prime recipients inherit the subrecipient shortfall whether or not they agreed to. When a community partner discovers that its 15 percent is now 10 percent, the gap does not vanish. It becomes a negotiation with the prime, and primes frequently end up covering it from institutional funds to keep the partnership intact.

Set that against the direction of travel elsewhere in federal grants policy, where OMB's proposed rule simultaneously strengthened subaward reporting and pass-through monitoring obligations at 2 CFR 200.332. Pass-through entities are being asked to do more subrecipient oversight while recovering less of the cost of doing it.

Concrete Steps for the Next Ten Weeks

Audit your accounting configuration this week, by agency. The specific question is whether your system applies a single subaward F&A threshold or branches on funder. If it is single-valued and set to $50,000, every NIH subaward processed since April 2026 is miscalculated. This is a one-afternoon diagnostic that can prevent a multi-year audit finding.

Inventory NIH subawards issued at 15 percent de minimis. Pull every NIH subaward executed between the 2025 flexibility notice and the April 2026 rescission where the subrecipient had no negotiated rate. Each is a candidate for amendment, and each needs an explicit decision about who absorbs the difference.

Rebudget pending NIH proposals before just-in-time. If an application is under review with a budget built on a $50,000 base or 15 percent de minimis, fix it now rather than at award negotiation. Finding the money inside an already-scoped project is much harder than adjusting a proposal that has not been awarded.

Document your retroactivity position in writing. Given COGR's flagged ambiguity, decide — and record the reasoning for — whether you are applying the rescission prospectively from April 20, 2026 or retroactively, and be ready to defend it consistently. Inconsistency across awards is what turns a judgment call into a finding.

Tell your subrecipients. Small organizations are not reading NIH Guide notices. A prime that explains the change before issuing a reduced subaward preserves a partnership; one that silently reduces the rate does not.

Keep the dual-rate idea in proportion. Some advisers have floated negotiating separate NIH and non-NIH indirect cost rates. It is technically available, but the Section 224 constraint operates on the base, not the rate — an approved rate still applies only to the first $25,000 of each NIH subaward. For most institutions the administrative cost of maintaining two rate agreements exceeds the recovery.

What December 11 Changes, and What It Does Not

The honest answer is: less than people hope.

Even if full-year FY 2027 appropriations arrive in December, the Section 224 rider is an annual appropriations provision that has been carried forward repeatedly and enjoys broad bipartisan support precisely because it functions as a shield against indirect-cost cuts. There is no constituency arguing to drop it, and dropping it would reopen the rate-cap fight. The most likely outcome is that it carries into FY 2027 unchanged, and NIH's $25,000 and 10 percent figures persist alongside the rest of the government's $50,000 and 15 percent.

The second lever, the Uniform Grants Regulation, is frozen by Section 157 until December 11 and faces an uncertain path thereafter. Even a finalized UGR would not override an appropriations rider directing NIH to apply 45 CFR 75 as of Q3 FY 2017. Statute beats regulation.

So the planning assumption for FY 2027 should be that the split is permanent until Congress changes the rider, not that it is a temporary artifact awaiting cleanup. Institutions that build the agency-branching logic into their systems now will stop losing money and stop accumulating audit exposure. Those waiting for harmonization are waiting on a legislative change nobody has proposed.

The broader point for anyone budgeting federal awards right now: the indirect-cost rules are no longer uniform, the word "Uniform" in the guidance notwithstanding. Treat agency identity as a budget parameter. For a view of how the rest of the FY 2026 fiscal freeze is landing on award levels themselves, see our analysis of NOT-OD-26-131 and the authorization to fund below your Notice of Award. And if you are looking to spread risk across funders whose indirect cost treatment is not pinned to a 2017 snapshot, Granted is built for exactly that kind of search.